NICE TAs

13/08/2020

TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (replaced TA222)

13/08/2020

TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction

13/08/2020

TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (replaced TA205)

13/08/2020

TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma

13/08/2020

TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

13/08/2020

TA461: Roflumilast for treating chronic obstructive pulmonary disease (replaced TA244)

13/08/2020

TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

13/08/2020

TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

13/08/2020

TA274: Ranibizumab for treating diabetic macular oedema (replaced TA237)

13/08/2020

TA236: Ticagrelor for the treatment of acute coronary syndromes

13/08/2020

TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults

13/08/2020

TA149: Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)

13/08/2020

TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

12/08/2020

TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation

12/08/2020

TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

12/08/2020

TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus.

12/08/2020

TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

12/08/2020

NG28: Type 2 diabetes in adults: management

12/08/2020

TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

12/08/2020

TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (replaced TA255)